2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT) PET has been proven to be of value in diagnosis and assessment of glioma grading, in differentiating tumor recurrence from necrosis, in response assessment and in predicting overall survival (OS) in the primary high grade glioma. In this study, we evaluated the value of [(18)F] FLT PET-CT in predicting the OS of patients with recurrent malignant glioma.

          Related collections

          Author and article information

          Journal
          Nucl. Med. Biol.
          Nuclear medicine and biology
          Elsevier BV
          1872-9614
          0969-8051
          Sep 2014
          : 41
          : 8
          Affiliations
          [1 ] Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong, China; Key Laboratory of Radiation Oncology of Shandong Province, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
          [2 ] Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
          [3 ] Key Laboratory of Radiation Oncology of Shandong Province, Shandong Cancer Hospital and Institute, Jinan, Shandong, China; Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
          [4 ] Key Laboratory of Radiation Oncology of Shandong Province, Shandong Cancer Hospital and Institute, Jinan, Shandong, China; Department of Radiology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
          [5 ] Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong, China; Key Laboratory of Radiation Oncology of Shandong Province, Shandong Cancer Hospital and Institute, Jinan, Shandong, China. Electronic address: sdyujinming@126.com.
          Article
          S0969-8051(14)00266-2
          10.1016/j.nucmedbio.2014.04.134
          24929963
          d021339e-7203-4467-ad5a-4f5eb644ea11
          History

          Survival prediction,Recurrence,Malignant glioma,MRI,[(18)F] FLT PET

          Comments

          Comment on this article